Class I IHC devices should not require 510(k) clearance, Incstar says.
This article was originally published in The Gray Sheet
Executive Summary
CLASS I IHC STAIN EXEMPTION FROM 510(K) REQUIREMENTS should be adopted by FDA, Incstar says in recent comments on FDA's proposed rule to classify immunohistochemical stains. Because Class I IHC devices are used for "minor clinical or decision making purposes," the company maintains that 510(k) exemption of IHC Class I devices "would save time, effort and money of both industry and FDA with little or no risk to health care."
You may also be interested in...
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.